XBiotech Inc.
XBIT
$2.95
-$0.19-6.05%
| Weiss Ratings | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.98 | |||
| Price History | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -10.61% | |||
| 30-Day Total Return | -5.45% | |||
| 60-Day Total Return | -34.15% | |||
| 90-Day Total Return | -54.55% | |||
| Year to Date Total Return | -29.26% | |||
| 1-Year Total Return | -64.92% | |||
| 2-Year Total Return | -14.74% | |||
| 3-Year Total Return | -67.93% | |||
| 5-Year Total Return | -70.26% | |||
| 52-Week High % Change | -68.47% | |||
| 52-Week Low % Change | 6.80% | |||
| Price | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.96 | |||
| 52-Week Low Price | $2.94 | |||
| 52-Week Low Price (Date) | Feb 24, 2025 | |||
| 52-Week High Price (Date) | Apr 10, 2024 | |||
| Valuation | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 95.73M | |||
| Enterprise Value | -66.70M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.27 | |||
| Earnings Per Share Growth | 56.00% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.53 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $2.95 | |||
| Enterprise Value/EBITDA (TTM) | 1.64 | |||
| Enterprise Value/EBIT | 1.57 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 30.47M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | $2.47 | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | $2.47 | |||
| Company Info | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 512 386 2900 | |||
| Address | 5217 Winnebago Lane Austin, TX 78744 | |||
| Website | www.xbiotech.com | |||
| Country | United States | |||
| Year Founded | 2005 | |||
| Profitability | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -12.47% | |||
| Return on Equity | -- | |||
| Income Statement | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -40.73M | |||
| EBIT (TTM) | -42.47M | |||
| Net Income (TTM) | -38.53M | |||
| Net Income Avl. to Common (TTM) | -38.53M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -126.71% | |||
| EPS Diluted (TTM) | -1.27 | |||
| EPS Diluted Growth (Q YOY) | -121.80% | |||
| Balance Sheet | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 172.68M | |||
| Cash Per Share (Q) | $5.67 | |||
| Total Current Assets (Q) | 174.57M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 182.27M | |||
| Current Ratio (Q) | 11.557 | |||
| Book Value Per Share (Q) | $5.98 | |||
| Total Assets (Q) | 199.09M | |||
| Total Current Liabilities (Q) | 15.11M | |||
| Total Debt (Q) | 10.25M | |||
| Total Liabilities (Q) | 16.83M | |||
| Total Common Equity (Q) | 182.27M | |||
| Cash Flow | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.30M | |||
| Cash from Financing (TTM) | 10.45M | |||
| Net Change in Cash (TTM) | -27.35M | |||
| Levered Free Cash Flow (TTM) | -26.17M | |||
| Cash from Operations (TTM) | -30.96M | |||
